E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Dementia of the Alzheimer type |
Dementie van het type Alzheimer |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10012271 |
E.1.2 | Term | Dementia Alzheimer's type |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective of the present study is to examine the effects of treatment with galantamine among patients with AD on the variability and stability of walking (with and without dual-task), functional mobility, standing balance, and cognitive functions (e.g. attention and executive functions). |
Het doel van het onderzoek is om te onderzoeken wat bij patienten met de ziekte van Alzheimer de effecten zijn van de ACER galantamine op de variabiliteit en stabiliteit van het looppatroon (met en zonder dubbeltaken), functionele mobiliteit, stabalans, en cognitieve functies (m.n. aandacht en executieve functies). |
|
E.2.2 | Secondary objectives of the trial |
Furthermore, the relation between variability and stability of walking with and without dual-tasking, and cognitive functions (e.g. attention and executive functions), and activities of daily living, will be examined. |
Tevens wordt de relatie tussen de verschillende loopparameters (zie methodesectie van het onderzoeksprotocol), cognitie, activiteiten van het dagelijks leven en vallen, onderzocht. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients will be included for the present study when they are (a) aged 65 years or older; (b) diagnosed with mild to moderate Alzheimer's disease (according to the criteria of the DSM-IV and the NINCDS-ADRDA); and (c) able to walk for at least 160 meter without using any assistive device. |
Patienten worden geincludeerd voor de studie als zij (a) 65 jaar of ouder zijn; (b) gediagnosticeerd zijn met milde tot matige ziekte van Alzheimer (volgens de criteria van de DSM-IV en de NINCDS-ADRDA); en (c) ten minste 160 meter kunnen lopen zonder hulpmiddelen te gebruiken. |
|
E.4 | Principal exclusion criteria |
Patients will be excluded from the present study when they (a) have had any treatment with acetylcholine esterase inhibitors during the three months before inclusion; (b) have any mobility problems due to (lateral) neurological or orthopedic disorders with function limitations of one or both legs; (c) have severe visual impairments; or (d) are unable to understand and follow simple verbal instructions. |
Patienten worden geëxcludeerd voor de studie als zij (a) een behandeling met een acetylcholinesteraseremmer hebben gehad in de drie maanden voorafgaand aan inclusie; (b) mobiliteitsproblemen hebben door (laterale) neurologische of orthopedische aandoeningen aan een of beide benen; (c) ernstige visuele beperkingen hebben; of (d) niet in staat zijn simpele verbale instucties te begrijpen en op te volgen. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Statistically significant difference in outcome parameters between intervention and control group after 6 months of galantamine use. |
Statistisch significant verschil in uitkomstmaten tussen de interventie en controlegroep na 6 maanden galantamine-gebruik. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After 12 months, a half-time evaluation will be done. |
Na 12 maanden, wordt een tussentijdse evaluatie gedaan. |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
geen behandeling |
no treatment |
|
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Laatste bezoek van de laatste patient. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |